Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Barrack: We call upon Druze, Bedouins, and Sunnis to put down their weapons and together with other minorities build a new and united Syrian identity building peace and prosperity with their neighbors
US Special Envoy to Syria Tom Barrack: Israeli Prime Minister Benjamin Netanyahu and Syrian President Ahmad al-Sharaa supported by the US have agreed to a ceasefire embraced by Türkiye, Jordan, and their neighbors
YAF spokesperson Brigadier General Yahya Saree: We carried out a top-tier operation targeting Ben Gurion Airport in Lydd with a Palestine 2 hypersonic ballistic missile
Israeli media: Israelis in the Gush Dan area and al-Quds were asked to enter shelters immediately
Sirens sound in Tel Aviv and occupied al-Quds after a missile was launched from Yemen
Sheikh Qassem: We are ready to defend ourselves if 'Israel' attacks us in a way that we believe calls for us to defend ourselves
Sheikh Qassem: "Israel" will never be handed over our weapons
Sheikh Qassem: He who refuses so and accepts humiliation, that is their own business, but for us, we will not accept humiliation. We have made great sacrifices, and our strength has helped us achieve this result
Sheikh Qassem: Be patient with the issue of exclusivity of arms with the state in the face of the great danger that will not spare Lebanon; let us speak with one voice and work for the sake of priority
Sheikh Qassem: Lebanon faces three real dangers: 'Israel', ISIS tools on the eastern border, and US tyranny

Alzheimer's drug approval optimistic amid promising results

  • By Al Mayadeen English
  • Source: Agencies
  • 17 Jul 2023 23:44
3 Min Read

Following clinical trial results, another Alzheimer's drug proven to slow cognitive decline is one step closer to US approval.

  • x
  • A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. New research shows another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening. (AP)
    A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. (AP)

As a consequence of clinical trial findings that were published in a reputable publication on Monday, a second Alzheimer's medication that has been shown to reduce cognitive loss moved one step closer to US approval.

After years of little advancement in the field, many experts have welcomed the results as significant advances. However, others have advised caution, characterizing the advantages as limited while highlighting the high prices and risks of life-threatening side effects.

A study published in the Journal of the American Medical Association (JAMA) found that the medicine donanemab reduced the progression of symptoms over an 18-month period by 35% in comparison to placebo in approximately 1,200 persons with early-stage Alzheimer's disease.

Read: 19-year-old Chinese man becomes youngest patient with Alzheimer's

Results from cognitive tests and participants' capacity to complete daily tasks were used to gauge this. Drugmaker Eli Lilly, which said it anticipates regulatory action in the United States by the end of the year, produces the medication, which is administered intravenously every four weeks.

The release of the new research coincides with the US Food and Drug Administration's decision to allow Leqembi, a medication created by Biogen and Eisai, to be covered by Medicare, the nation's sponsored insurance program for the elderly.

Both function by focusing on the protein amyloid beta, which damages cognition when it builds up in the brain.

Related News

UN report reveals cocaine in upward trend, meth market expands

288 people arrested by Europol in massive dark web crackdown

"These first-generation drugs are by no means perfect, but represent an important breakthrough," interim director of the UK Dementia Research Institute, Giles Hardingham, said in a statement.

However, he added that it was equally crucial to understand that Alzheimer's is a complex illness and that amyloid beta was merely one factor in its development.

However, Eric Widera of the University of California, San Francisco, and colleagues argued that it was too early to conclude that the new medications would be helpful in the long run. Such opinions appeared in an editorial that was published alongside the new results in JAMA.

They claimed that Donanemab and Leqembi, also known as lecanemab, do not treat Alzheimer's disease but rather cause "slightly less worsening" in patients.

"The modest benefits would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. However, they are none of these," the authors wrote.

Patients will still be responsible for thousands of dollars in out-of-pocket expenses even after Medicare covers 80% of the expenditures.

Additionally, three deaths that were most likely brought on by the therapies that cause brain bleeds occurred in the investigations of donanemab and Leqembi.

Given that anti-amyloid therapies also speed up brain atrophy, research indicates that it will be critical to gather more information as the treatments enter the real world to determine whether they continue to decrease cognitive decline past 18 months or if they have the opposite effect.

Additionally, since 96% of the patients in the donanemab trial were white despite the fact that Black and Latino persons had a much greater prevalence of Alzheimer's, this means that important demographics still remain understudied.

  • Eli Lilly
  • Alzheimer's Disease
  • Drug

Most Read

Algerian nurse stabbed in Germany

Murder of Algerian nurse in Germany sparks outcry, demands for justice

  • Europe
  • 14 Jul 2025
Credible reports, including some from Israeli media itself, indicate that Tel Aviv had pinned its hopes on what can only be described as a delusional plan. (Al Mayadeen English; Illustrated by Batoul Chamas)

Jebraily: Iran strikes rewrote regional deterrence rules - Exclusive

  • MENA
  • 15 Jul 2025
Al-Qassam Brigades fighters confront Israeli soldiers in Beit Lahia, northern Gaza, undated (Al-Qassam Brigades Military Media)

3 Israeli soldiers killed amid Gaza battles: Israeli media

  • Palestine
  • 14 Jul 2025
Al Mayadeen: UN Palestine Inquiry members reportedly resigned

Exclusive: UN Palestine Inquiry members reportedly resigned

  • Politics
  • 15 Jul 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
The US Capitol, Wednesday, July 16, 2025, in Washington (AP)
Politics

Congress set to weaken oversight on foreign US arms sales

Only quarter of Americans say Trump policies helped them: Poll
US & Canada

Only quarter of Americans say Trump policies helped them: Poll

UK charities fund Israeli settlement expansion in occupied West Bank
Palestine

UK charities fund Israeli settlement expansion in occupied West Bank

Calls grow to remove Netanyahu from High School hall of fame
Politics

Calls grow to remove Netanyahu from high school Hall of Fame

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS